Penumbra (PEN)

• Market cap: $10.1B
• 1 day: 0.53%
• 5 days: 10.50%
• 1 month: 6.52%
• 3 months: 30.37%
• 6 months: 29.76%
• Year to date: 9.88%
• 1 year: 2.51%
• 5 years: 64.44%
• 10 years: 538.47%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Employees: 4,200

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

17% more call options, than puts

Call options by funds: $68.5M | Put options by funds: $58.6M

6% more capital invested

Capital invested by funds: $6.51B [Q2] → $6.87B (+$363M) [Q3]

9% less first-time investments, than exits

New positions opened: 51 | Existing positions closed: 56

2.47% less ownership

Funds ownership: 93.48% [Q2] → 91.0% (-2.47%) [Q3]

3% less funds holding

Funds holding: 339 [Q2] → 328 (-11) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 139

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $245 7% downside
• Avg. target: $271 3% upside
• High target: $323 22% upside

8 analyst ratings

• positive: 7 88%
• neutral: 1 13%
• negative: 0 0%

Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target	8% upside $285	Buy Maintained	18 Dec 2024
Oppenheimer Steve Lichtman 100% 1-year accuracy 2 / 2 met price target	4% upside $275	Outperform Initiated	17 Dec 2024
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target	7% downside $245	Neutral Maintained	11 Dec 2024
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target	4% upside $275	Overweight Upgraded	11 Dec 2024
Canaccord Genuity Jason Mills 57% 1-year accuracy 4 / 7 met price target	22% upside $323	Buy Maintained	9 Dec 2024